204 related articles for article (PubMed ID: 38790963)
1. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T; Kubo M; Takahashi K; Wamata R; Iwamoto Y; Iwamoto H; Katakura Y; Sanada J; Fushimi Y; Shimoda M; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2024; 2024():5880589. PubMed ID: 38223524
[TBL] [Abstract][Full Text] [Related]
7. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.
Yamada H; Yoshida M; Suzuki D; Funazaki S; Nagashima S; Masahiko K; Kiyoshi O; Hara K
Diabetes Ther; 2022 Oct; 13(10):1779-1788. PubMed ID: 36006593
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
Thethi TK; Pratley R; Meier JJ
Diabetes Obes Metab; 2020 Aug; 22(8):1263-1277. PubMed ID: 32267058
[TBL] [Abstract][Full Text] [Related]
11. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
[TBL] [Abstract][Full Text] [Related]
13. A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes.
Yanai H; Hakoshima M; Adachi H; Katsuyama H
Cardiol Res; 2022 Oct; 13(5):303-308. PubMed ID: 36405226
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus].
Khamnueva LY; Andreeva LS
Probl Endokrinol (Mosk); 2023 May; 69(2):38-46. PubMed ID: 37448270
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
[TBL] [Abstract][Full Text] [Related]
16. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM
Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123
[TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
Williams DM; Ruslan AM; Khan R; Vijayasingam D; Iqbal F; Shaikh A; Lim J; Chudleigh R; Peter R; Udiawar M; Bain SC; Stephens JW; Min T
Diabetes Ther; 2021 Mar; 12(3):801-811. PubMed ID: 33565043
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
19. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
20. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
Metab Syndr Relat Disord; 2024 Jun; ():. PubMed ID: 38868900
[No Abstract] [Full Text] [Related]
[Next] [New Search]
